SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017)
SELLAS Life Sciences' (SLS) quarterly Long-Term Debt Issuances came in at -$4.4 million in Q2 2017, down 118.82% year-on-year from $23.6 million in Q2 2016, and down 200.0% on a QoQ basis from $4.4 million in Q1 2017.
SELLAS Life Sciences (SLS) Long-Term Debt Issuances (2016 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 2 years of Long-Term Debt Issuances data on file, last reported at -$4.4 million in Q2 2017.
- On a quarterly basis, Long-Term Debt Issuances fell 118.82% year-over-year to -$4.4 million in Q2 2017; TTM through Sep 2017 was -$22.1 million, a 193.66% decrease from a year earlier, with the FY2016 full-year figure at $1.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q2 2017 stood at -$4.4 million, down from $4.4 million in the prior quarter.
- Over the last five years, Long-Term Debt Issuances for SLS reached as high as $23.6 million in Q2 2016 and fell as low as -$22.1 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | -4.45 Mn |
| Jun 30, 2017 | -4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Mar 31, 2017 | 4.45 Mn |
| Dec 31, 2016 | -22.14 Mn |
| Dec 31, 2016 | -22.14 Mn |
| Jun 30, 2016 | 23.64 Mn |
| Jun 30, 2016 | 23.64 Mn |